<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388437</url>
  </required_header>
  <id_info>
    <org_study_id>REC 202</org_study_id>
    <nct_id>NCT03388437</nct_id>
  </id_info>
  <brief_title>Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation</brief_title>
  <official_title>Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation: A Randomised Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Fahad Armed Forces Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Fahad Armed Forces Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive respiratory support has been emerging in the management of respiratory distress&#xD;
      syndrome (RDS) in preterm infants to minimise the risk of lung injury. Intermittent positive&#xD;
      pressure ventilation (NIPPV) provides a method of augmenting continuous positive airway&#xD;
      pressure (CPAP) by delivering ventilator breaths via nasal prongs.It may increase tidal&#xD;
      volume, improve gas exchange and reduce work of breathing. However, NIPPV may associate with&#xD;
      patient-ventilator asynchrony that can cause poor tolerance and risk of intubation. It may&#xD;
      also in increased risk of pneumothorax and bowel perforation because of increase in&#xD;
      intrathoracic pressure.&#xD;
&#xD;
      On the other hand, neurally adjusted ventilatory assist (NAVA) is a newer mode of&#xD;
      ventilation, which has the potential to overcome these challenges. It uses the electrical&#xD;
      activity of the diaphragm (EAdi) as a signal to synchronise the mechanical ventilatory&#xD;
      breaths and deliver an inspiratory pressure based on this electrical activity. Comparing&#xD;
      NI-NAVA and NIPPV in preterm infants, has shown that NI-NAVA improved the synchronization&#xD;
      between patient and ventilator and decreased diaphragm work of breathing .&#xD;
&#xD;
      There is lack of data on the use of NI-NAVA in neonates post extubation in the literature. To&#xD;
      date, no study has focused on short-term impacts. Therefore, it is important to evaluate the&#xD;
      need of additional ventilatory support post extubation of NI-NAVA and NIPPV and also the risk&#xD;
      of developing adverse outcomes.&#xD;
&#xD;
      Aim:&#xD;
&#xD;
      The aim is to compare NI-NAVA &amp; NIPPV in terms of extubation failure in infants&lt; 32 weeks&#xD;
      gestation.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Investigators hypothesized that infants born prematurely &lt; 32 weeks gestation who extubated&#xD;
      to NI-NAVA have a lower risk of extubation failure and need of additional ventilatory&#xD;
      support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Randomised controlled trial&#xD;
&#xD;
      Study Setting: single center NICU level III, KFAFH tertiary care center , Jeddah Saudi Arabia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial&#xD;
A web generated a block randomisation list.&#xD;
A block of 4, stratification based on GA, gender &amp; antenatal steriods&#xD;
Sequentially numbered, opaque and sealed envelopes&#xD;
Restricted access to envelopes</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>72 hours</time_frame>
    <description>Treatment failure during the first 72 hours post-extubation.&#xD;
Reintubation (failure of extubation) within 72 hours' post extubation.&#xD;
Treatment failure is defined as:&#xD;
Hypoxia (FiO 2 requirement &gt; 0.35)&#xD;
Respiratory acidosis defined as pH &lt; 7.2 &amp; PCo2&gt; 60 mmHg&#xD;
Major apnea requiring mask ventilation or &gt; 4 episodes/ hour.&#xD;
The protocol will discontinue according to treatment failure criteria as mentioned above.&#xD;
Rescue treatment with NIPPV will be allowed and will be considered as treatment failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death prior to discharge</measure>
    <time_frame>90 days from birth</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular haemorrhage IVH (grades III &amp; IV)</measure>
    <time_frame>7 days after extubation</time_frame>
    <description>defined as haemorrhage causing ventricular dilatation with or without brain parenchymal involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumothorax</measure>
    <time_frame>7 days after extubation</time_frame>
    <description>diagnosed radiologically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia (BPD)</measure>
    <time_frame>36 weeks' postmenstrual age</time_frame>
    <description>defined as requirement for supplemental oxygen at 28 days of life or requirement for supplemental oxygen at 36 weeks' postmenstrual age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>7 days after extubation</time_frame>
    <description>defined according to modified Bell's criteria (stage 2 to 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal perforation</measure>
    <time_frame>7 days after extubation</time_frame>
    <description>diagnosed radiologically or at operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial sepsis</measure>
    <time_frame>7 days after extubation</time_frame>
    <description>defined as positive blood or cerebrospinal fluid (CSF) cultures taken after five days of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of prematurity (ROP)</measure>
    <time_frame>40 weeks corrected postnatal age</time_frame>
    <description>stage 3 or greater (International classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation or Length of stay (in days)</measure>
    <time_frame>From admission to first discharge from hospital, assessed up to 6 months</time_frame>
    <description>Number of days in hospital until first discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Prematurity</condition>
  <condition>Respiratory Failure</condition>
  <condition>Ventilator Lung; Newborn</condition>
  <arm_group>
    <arm_group_label>NI-NAVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum &lt; 5 for 72 hours post extubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIPPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NI-NAVA</intervention_name>
    <description>Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.&#xD;
The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter &amp; positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation</description>
    <arm_group_label>NI-NAVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIPPV</intervention_name>
    <description>Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.&#xD;
The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter &amp; positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation</description>
    <arm_group_label>NIPPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Born less than 32 weeks gestation with respiratory distress syndrome (RDS) and&#xD;
             requiring endotracheal tube and mechanical ventilation.&#xD;
&#xD;
          2. Less than two weeks old&#xD;
&#xD;
          3. First extubation attempt&#xD;
&#xD;
          4. CRIB score 0-5&#xD;
&#xD;
          5. Written-informed parental consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major congenital malformations or respiratory abnormalities&#xD;
&#xD;
          2. Neuromuscular disease&#xD;
&#xD;
          3. phrenic nerve palsy&#xD;
&#xD;
          4. Intraventricular hemorrhage (IVH) grade III or IV&#xD;
&#xD;
          5. Absence of informed consent&#xD;
&#xD;
          6. Out born infants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raniah Aljeaid</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Fahad Armed Forces Hospital Jeddah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nisreen Kafi</last_name>
    <role>Study Director</role>
    <affiliation>King Fahad Armed Forces Hospital Jeddah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fawzia Sabbagh</last_name>
    <role>Study Director</role>
    <affiliation>King Fahad Armed Forces Hospital Jeddah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mai Abu Seoud</last_name>
    <role>Study Chair</role>
    <affiliation>King Fahad Armed Forces Hospital Jeddah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Fahad Armed Forces Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21159</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <results_reference>
    <citation>Lee J, Kim HS, Jung YH, Shin SH, Choi CW, Kim EK, Kim BI, Choi JH. Non-invasive neurally adjusted ventilatory assist in preterm infants: a randomised phase II crossover trial. Arch Dis Child Fetal Neonatal Ed. 2015 Nov;100(6):F507-13. doi: 10.1136/archdischild-2014-308057. Epub 2015 Jul 15.</citation>
    <PMID>26178463</PMID>
  </results_reference>
  <results_reference>
    <citation>Stein H, Howard D. Neurally adjusted ventilatory assist in neonates weighing &lt;1500 grams: a retrospective analysis. J Pediatr. 2012 May;160(5):786-9.e1. doi: 10.1016/j.jpeds.2011.10.014. Epub 2011 Dec 3.</citation>
    <PMID>22137670</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 16, 2017</study_first_submitted>
  <study_first_submitted_qc>December 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Fahad Armed Forces Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Raniah Aljeaid</investigator_full_name>
    <investigator_title>Neonatal Fellow</investigator_title>
  </responsible_party>
  <keyword>Non-invasive Neurally Adjusted Ventilatory Assist NI-NAVA</keyword>
  <keyword>Nasal Intermittent Positive Pressure Ventilation NIPPV</keyword>
  <keyword>post extubation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 31, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03388437/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

